NCT01218516 2020-08-20A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungMorphotekPhase 2 Completed130 enrolled 11 charts
NCT00318370 2015-09-09Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyMorphotekPhase 2 Completed58 enrolled 12 charts
NCT01203618 2013-11-04Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary AdenomasMorphotekPhase 2 Withdrawn